PHARMALY
ActiveFinancials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 16-12-2025 at the NBB
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Investments
| Item | 30-06-2025 |
|---|---|
| Tangible fixed assets | €33,913 |
| Depreciation and write-downs of the year | €1,855 |
Source: notes to the 2025 annual accounts (statement of fixed assets)
| Line | 2025 |
|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1,855 |
| Other operating charges640/8 | €254 |
| Gross operating margin9900 | €20,555 |
| Operating profit (loss)9901 | €18,446 |
| Financial charges65/66B | €427 |
| Recurring financial charges65 | €427 |
| Profit (loss) for the period before taxes9903 | €18,019 |
| Income taxes67/77 | €4,500 |
| Profit (loss) for the period9904 | €13,519 |
| Profit (loss) for the period to be appropriated9905 | €13,519 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €56,461 | |
| Fixed assets21/28 | €32,058 | |
| Tangible fixed assets22/27 | €32,058 | |
| Leasing and similar rights25 | €32,058 | |
| Current assets29/58 | €24,403 | |
| Amounts receivable within one year40/41 | €11,140 | |
| Trade receivables40 | €8,140 | |
| Other amounts receivable41 | €3,000 | |
| Cash at bank and in hand54/58 | €12,910 | |
| Deferred charges and accrued income490/1 | €353 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €56,461 | |
| Equity10/15 | €16,019 | |
| Contributions10/11 | €2,500 | |
| Profit (loss) carried forward14 | €13,519 | |
| Amounts payable17/49 | €40,442 | |
| Amounts payable after more than one year17 | €26,750 | |
| Financial debts170/4 | €26,750 | |
| Amounts payable within one year42/48 | €13,660 | |
| Current portion of amounts payable after more than one year42 | €6,155 | |
| Trade debts44 | €1,571 | |
| Suppliers440/4 | €1,571 | |
| Taxes, remuneration and social security45 | €5,933 | |
| Taxes450/3 | €5,933 | |
| Accrued charges and deferred income492/3 | €32 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €13,519 |
| + Depreciation and write-downs630 | €1,855 |
| Operating cash flow (approximation) | €15,374 |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 2,390 companies had the same profile as PHARMALY has now. Two years later, 96.7% were still going and 1.2% had gone bankrupt.
- Micro
- under 2 years old
- solvency 10 to 30%
- a profit of 5% of the balance sheet or more
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PHARMALY itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,390 companies, not a prediction for PHARMALY. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | abbreviated format | 16-12-2025 | 2025-00582792 |